摘要
目的探讨宫颈癌患者血清和组织（转化生长因子β）TGFβ对激素替代治疗（HRT）的影响。方法用ELISA法对83例HRT和NHRT宫颈癌患者在治疗的不同时期及40例对照进行血清TGFβ含量测定，并采用免疫组化方法对83例宫颈癌病灶以及正常宫颈组织30例进行TGF-β表达检测。结果宫颈癌患者血清及癌组织中TGFβ高于正常对照者。宫颈癌Ⅱb～Ⅲ期患者血清TGFβ含量明显高于Ⅰ～Ⅱa期患者，比较有显著性差异（P〈0．05）。不同临床病理因素内，宫颈癌组织TGFβ阳性表达率无显著性差异（P〉0．05）。在三个不同的时期（手术／放疗前、手术／放疗后、手术／放疗后半年），行HRT的宫颈癌与NHRT的宫颈癌血清TGFβ含量，均无显著性差异。宫颈癌组织TGFβ表达与患者血清TGFβ水平无相关。结论宫颈癌患者TGFβ与恶性肿瘤有关，但与HRT无明显相关。
Objective To explore the relationship between the contain of serum TGFβ and expression of carcinoma in HRT women with cervix cancer. Methods The level of serum TGFβ and expression of carcinoma were detected with enzyme-linked immunosorbent assay and immunohistinochemical staining respectively in 83 cases with cervix cancers and 40 normal control as well as 30 normal cervix issue. Results The contain of TGFβ in cervix cancer was higher than that in the normal. The contain of serum TGFβ in clinic stage Ⅱ b- Ⅲ was higher than that in Ⅰ - Ⅱ a, and contain of serum TGFβ with omentum metastasis than that without metastasis. There was not any significant relationship between expression of TGFβ and clinic-pathology. In different stages （before operation/radiotherapy, after operation/radiotherapy, in half and one year after operation/radiotherapy）, the level of serum TGFβ was not significantly different in the patients with cervix cancers between the group HRT and NHRT, P〈0. 05. There was not any significant relationship between TGFβ level of serum and expression of cancer. Conclusion TGFβ was almost similar in the patients with different TGFβ expression in cervix cancers issue. There was not significant relationship between HRT and TGFβ level of serum cervix cancer.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2006年第6期422-424,476,共4页
Cancer Research on Prevention and Treatment
基金
广西壮族自治区科技厅攻关课题(桂科攻9817101)
